Ethyl 4-[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]-1,3-thiazole-2-carboxylate

Catalog No. :
ACSYNS692
CAS No. :
1803589-99-2
Molecular Formula :
C13H10N4O3S
Molecular Weight :
302.32

IUPAC Name:ethyl 4-(3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)thiazole-2-carboxylate

Ethyl 4-[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]-1,3-thiazole-2-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
50mg95%$302.00Login to see priceInquiryInquiry
100mg95%$441.00Login to see priceInquiryInquiry
250mg95%$621.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameEthyl 4-[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]-1,3-thiazole-2-carboxylate
IUPAC Nameethyl 4-(3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl)thiazole-2-carboxylate
MDL No.-
Molecular FormulaC13H10N4O3S
Molecular Weight302.32
SMILESO=C(C1=NC(C2=NC(C3=CC=NC=C3)=NO2)=CS1)OCC
InChI KeyHAKXTRKXQOTMSM-UHFFFAOYSA-N
Synonymethyl 4-[3-(pyridin-4-yl)-1,2,4-oxadiazol-5-yl]-1,3-thiazole-2-carboxylate;2-Thiazolecarboxylic acid, 4-[3-(4-pyridinyl)-1,2,4-oxadiazol-5-yl]-, ethyl ester
CAS No.1803589-99-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACSYNS692 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACWJEN130 route compound structure diagram
    ACWJEN13016982-21-1 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACSYNS692 route product structure diagram
    ACSYNS6921803589-99-2
Inquiry

2. ACSYNS692 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACSYNS692 route product structure diagram
    ACSYNS6921803589-99-2
Inquiry

Comments (0)